Synergistic effects of low doses of histatin 5 and its analogues on amphotericin B anti-mycotic activity

Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology

Volumn 78, Issue 2, 2000, Pages 163-169

  Hof, Wim van't ^a   Reijnders, Ingrid M ^a   Helmerhorst, Eva J ^a   Walgreen Weterings, Els ^a   Simoons Smit, Ina M ^b   Veerman, Enno C I ^a   Nieuw Amerongen, Arie V ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amphotericin B; Antimicrobial peptides; Candida albicans; Histatin; Synergism

Indexed keywords

AMPHOTERICIN B; CATION; DRUG ANALOG; DVHAR 4; DVHAR 5; FLUCONAZOLE; FLUCYTOSINE; HISTATIN; MAGAININ 2; PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; ASSAY; CANDIDA; CANDIDA ALBICANS; CONTROLLED STUDY; CRYPTOCOCCUS; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENTIATION; FUNGUS GROWTH; FUNGUS MUTANT; GROWTH INHIBITION; HEMOLYSIS; HOST CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; STANDARDIZATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; FLUCONAZOLE; FLUCYTOSINE; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; SALIVARY PROTEINS; XENOPUS PROTEINS;

EID: 0034521229     PISSN: 00036072     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026572128004     Document Type: Article

References (38)

1. Antifungal resistance trends towards the year 2000
2. Systemic antifungal therapy: Past, present and future
3. Disseminated candidiasis due to amphotericin B-resistant Candida albicans
4. Antimicrobial combinations
5. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy
6. Potential new antifungal agents
7. Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose
8. Peptide antibiotics
9. Synthetic histatin analogs with broad-spectrum antimicrobial activity
10. Amphotericin B and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antimicrobial peptides
11. A critical evaluation of the lytic activity of cationic antimicrobial peptides against Candida albicans cells and human erythrocytes
12. In vitro antifungal activity and cytotoxicity of a novel membrane-active peptide
13. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids
14. Antifungal agents in the 1990s
15. Therapeutic peptides: The devil is in the details. The next generation of peptide pharmaceuticals may push manufacturing processes beyond their limits
16. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients
17. 6-desaturation
18. Update on antifungal resistance
19. Failure of all antifungal therapy for infection due to Candida albicans: A new AIDS-related problem?
20. Amphotericin B resistance testing of Candida spp.: A comparison of methods
21. A comparative study on the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus
22. Molecular biological characterization of an azole-resistant Candida glabrata isolate
23. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
24. Histatins, a novel family of histidine-rich proteins in human parotid secretion
25. Amphotericin B-induced oxidative damage and killing of Candida albicans
26. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
27. Antimicrobial properties of peptides from Xenopus granular gland secretions
28. Resistance to amphotericin B - Emerging clinical and microbiological patterns
29. Studies on the mechanism of human salivary histatin 5 candidacidal activity with histatin 5 variants and azole-sensitive and - Resistant Candida species
30. Antifungal drug resistance in pathogenic fungi
31. Group of peptides that act synergistically with hydrophobic antibiotics against Gram-negative bacteria
32. Epitope mapping of the Dermatophagoides pteronyssinus house dust mite major allergen Der p II using overlapping synthetic peptides
33. Reference method for broth dilution anti-fungal susceptibility testing of yeasts: Tentative standard
34. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents
35. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation
36. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
37. Primary structure and anticandidal activity of the major histatin from parotid secretion of the subhuman primate, Macaca fascicularis
38. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor